Navigation Links
Ventus Medical Appoints John McCutcheon as President and CEO
Date:4/9/2009

- - Also Announces the expansion of PROVENT(R) Sleep Apnea Therapy in Limited US Markets

BELMONT, Calif., April 9 /PRNewswire/ -- Ventus Medical, Inc. a privately-held, medical device company, focused on transforming the Sleep Disordered Breathing market, today announced the appointment of John McCutcheon as President and Chief Executive Officer, effective April 20, 2009. The company also announced that current CEO Jeffrey Nugent will become Executive Chairman.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090409/SF96872LOGO)

Mr. McCutcheon joins Ventus Medical from Emphasys Medical where he was President and CEO for the past seven years. Previously, he was head of Sales and Marketing at Perclose, an Abbott Laboratories company and in senior marketing positions at Devices for Vascular Intervention and Baxter Healthcare.

"John is the ideal leader to drive the commercialization of PROVENT Therapy as a novel treatment of obstructive sleep apnea (OSA). He is a proven leader in the medical device field with nearly 25 years of experience," said Mr. Nugent. "Clinical studies have shown that PROVENT Therapy has the potential to improve the quality of life for millions of people around the world who suffer from this disorder," he added. "We are encouraged by the acceptance we are experiencing at both the physician and patient level at the sleep centers where PROVENT Therapy is currently available."

PROVENT Therapy has been cleared by the Food and Drug Administration and is indicated for the treatment of obstructive sleep apnea. PROVENT Therapy is a daily use, prescription device and works across mild, moderate, and severe OSA.

"I am pleased to join Ventus Medical at this exciting time in the Company's development," said John McCutcheon. "PROVENT Therapy is one of the most innovative products to be introduced into the sleep apnea market in years: it is a convenient, discreet and portable solution. We look forward to working closely with the medical community to meet the need for more patient-friendly, effective sleep apnea treatments."

PROVENT Therapy is currently available in a limited number of markets and is in the process of expanding with the assistance and support of professional sleep physicians in the United States.

Also, Ventus Medical has just been awarded the 2009 Medical Design Excellence Award which recognizes those companies responsible for the ground breaking innovations that are changing the face of healthcare.

Ventus Medical's investors include De Novo Ventures, Mohr Davidow Ventures and the Johnson & Johnson Development Corporation. Information on Ventus Medical and PROVENT Therapy can be found on www.ventusmedical.com and www.proventtherapy.com.


'/>"/>
SOURCE Ventus Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
Breaking Biology News(10 mins):